Levi Sandri Giovanni Battista, Ettorre Giuseppe Maria, Colasanti Marco, De Werra Edoardo, Mascianà Gianluca, Ferraro Daniele, Tortorelli Giovanni, Sciuto Rosa, Lucatelli Pierleone, Pizzi Giuseppe, Visco-Comandini Ubaldo, Vennarecci Giovanni
Division of General Surgery and Liver Transplantation, San Camillo Hospital Rome, Rome, Italy.
Division of Nuclear Medicine, IFO Regina Elena National Cancer Institute, Rome, Italy.
Hepatobiliary Surg Nutr. 2017 Feb;6(1):44-48. doi: 10.21037/hbsn.2017.01.08.
Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure.
From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center. One hundred and forty-three patients were transplanted for hepatocellular carcinoma (HCC) and in 22 cases patients were treated with Y90-RE before liver transplantation (LT), of them 4 with macrovascular invasion were included in this study.
The four patients had a complete response for the thrombosis, and were included in the waiting list within the Milan criteria. Means interval time between Y90-RE and LT was 15.86 months. No patient death was observed at Y90-RE procedure or at LT. We obtain a free-survival of 39.1 (range, 6-76) months. In all four cases the complete thrombosis regression was observed.
We reported a short series of patients transplanted after Y90-RE in patients with BCLC stage C. In our experience we achieved acceptable overall and disease-free survival. Eventually, Y90-RE seems to have a place in the downstaging strategy for LT candidates.
钇-90微球放射性栓塞术(Y90-RE)已被证明是治疗原发性肝癌的一种有效且安全的方法。根据巴塞罗那临床肝癌(BCLC)分期系统,存在大血管侵犯的患者被分期为BCLC-C期。本文介绍了该手术应用后的结果。
2002年1月至2015年12月,圣卡米洛医院中心共进行了367例肝移植手术。其中143例为肝细胞癌(HCC)患者接受肝移植,22例患者在肝移植(LT)前接受了Y90-RE治疗,本研究纳入了其中4例存在大血管侵犯的患者。
这4例患者血栓形成完全缓解,符合米兰标准并被列入等待名单。Y90-RE与LT之间的平均间隔时间为15.86个月。在Y90-RE手术或LT过程中均未观察到患者死亡。我们获得了39.1个月(范围6 - 76个月)的无瘤生存期。所有4例均观察到血栓完全消退。
我们报告了一组BCLC C期患者在Y90-RE后接受肝移植的简短病例系列。根据我们的经验,总体生存率和无病生存率均可接受。最终,Y90-RE似乎在肝移植候选者的降期策略中占有一席之地。